Aardvark Therapeutics

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies designed to inhibit hunger and treat metabolic diseases. Its lead compound, ARD-101, is an oral investigational drug that activates bitter taste receptors (TAS2Rs) in the digestive tract to trigger the local release of satiety hormones and suppress hunger. The company is focused on conditions including hyperphagia in rare diseases such as Prader-Willi Syndrome as well as general obesity, with the goal of becoming a leader in the treatment of hunger-associated metabolic disorders.